

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/737,544
				Filing Date	12/18/2000
				First Named Inventor	MARK B PEPYS
				Art Unit	1617
				Examiner Name	S. Wang
Sheet	1	of	1	Attorney Docket Number	068800-0275486

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		CHRISTNER ET AL., "Binding of Human Serum Amyloid P-Component to Phosphocholine," Archives of Biochem. and Biophys., Vol. 314 (No. 2), p. 337-343, (1 November 1994).		
		LUIZZO ET AL., "The Prognostic Value of C-Reactive Protein and Serum Amyloid a Protein in Severe Unstable Angina," The New England Journal of Medicine, Vol. 331 (No. 7), p. 417-424, (August 18, 1994).		
		PEPYS ET AL., "Targeting C-reactive protein for the treatment of cardiovascular disease," Nature, Vol. 440, p. 1217-1221, (27 April 2006).		
		HIRSCHFIELD ET AL., "Therapeutic inhibition of C-reactive protein-novel drugs novel mechanisms," Vol. 104 (No. 49), p. 65P-66P, (February 5, 2003).		
		PEPYS ET AL., "Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis," Nature, (London), p. 254-259, (16 May 2002).		
		Liu et al., "Positive interaction between 5-FU and FdUMP(10) in the inhibition of human colorectal tumour cell proliferation" Antisense and Nucleic Acid Drug Development, 9:481-486 (Abstract)		
		Koizumi et al., Biologically Active Oligodeoxynucleotides, Part 12: N20 Methylation of 2'-deoxyguanosines... Bioorganic & Medicinal Chem. Ltrs. Vol. 10, pp. 2213-2216 (2000)		
		Tolstikova et al. "Derivatives of bis-phosphonic acids as antidepressants" Doklady Akademii Nauk (Vol. 344, No. 4, pp.. 565-567 (1995) w/English Abstract		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.